We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Ebola Vaccine Found to Protect Monkeys

By Biotechdaily staff writers
Posted on 13 Aug 2003
A study has shown that a single dose of a fast-acting experimental vaccine against the Ebola virus was able to protect monkeys from the virus after only one month. More...
The study was reported in the August 7, 2003, issue of Nature.

Researchers had been pursuing a "prime-boost” vaccine strategy against a variety of infectious diseases. Prime-boost is a two-part process that comprises an injection of noninfectious genetic material from the disease-causing microbe to prime the immune system to respond, and several weeks later, an injection of attenuated carrier viruses containing key genes from the microbe to substantially boost the immune response. The boost produces a weaker immune response but is quicker. Since time is critical when fighting Ebola, they decided to test whether the boost's fast response alone was strong enough to protect against the virus.

Eight monkeys were immunized with a single injection, consisting of attenuated carrier viruses containing genes for important Ebola antiens. The monkeys were then injected with an Ebola virus strain. The single vaccine injection completely protected all eight animals against Ebola infection, even those who received high doses of the virus. The study was conducted by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and the United States Army Medical Research Institute of Infectious Diseases at Fort Detrick, MD, USA).

"This research has enormous public health implications not only because it might be used to limit the spread of Ebola virus but also because this vaccine strategy may be applied to other highly lethal viruses, such as the Marburg and Lassa fever viruses and the SARS Coronavirus, that cause acute disease outbreaks and require a rapid response,” said Anthony S. Fauci, M.D., director of NIAID.




Related Links:
National Institute of Allergy and Infectious Diseases

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.